John Murphy III
John Murphy is the President and CEO of the Association for Accessible Medicines (AAM), the preeminent global trade association representing the prescription generics and biosimilars industry. Under his leadership, AAM is dedicated to enhancing access to safe, high-quality, and affordable medication for all patients in need. John is at the forefront of AAM’s efforts to foster a sustainable and resilient supply chain for generics and biosimilars, while continuously striving to broaden the range of affordable medication options available globally from AAM members.
He previously served as Chief Policy Officer and Senior Healthcare Counsel at the Biotechnology Innovation Organization (BIO), where he led domestic and international policy initiatives and directed the legal affairs of BIO’s healthcare division.
John holds degrees from Villanova University and the Catholic University Columbus School of Law. His career also includes experience in healthcare regulatory and enforcement matters at Hogan Lovells, LLP, as well as serving as Assistant General Counsel for the Pharmaceutical Research and Manufacturers of America (PhRMA).
John Murphy is the President and CEO of the Association for Accessible Medicines (AAM), the preeminent global trade association representing the prescription generics and biosimilars industry. Under his leadership, AAM is dedicated to enhancing access to safe, high-quality, and affordable medication for all patients in need. John is at the forefront of AAM’s efforts to foster a sustainable and resilient supply chain for generics and biosimilars, while continuously striving to broaden the range of affordable medication options available globally from AAM members.
He previously served as Chief Policy Officer and Senior Healthcare Counsel at the Biotechnology Innovation Organization (BIO), where he led domestic and international policy initiatives and directed the legal affairs of BIO’s healthcare division.
John holds degrees from Villanova University and the Catholic University Columbus School of Law. His career also includes experience in healthcare regulatory and enforcement matters at Hogan Lovells, LLP, as well as serving as Assistant General Counsel for the Pharmaceutical Research and Manufacturers of America (PhRMA).
Articles: John Murphy III
2026: A Chance for the US to Lead on Biosimilars, Not Lag Behind
USA / John Murphy III, President and CEO of the Association for Accessible Medicines (AAM), argues that 2026 represents a pivotal moment for the United States to reclaim leadership in biosimilars. He outlines how recent FDA reforms could finally unlock competition, lower drug costs, and expand patient access, while warning that outdated regulatory barriers, patent tactics, and…
Generics & Biosimilars: Policymakers Must Align to Maintain the Backbone of US Healthcare
USA / John Murphy, III, president & CEO of the Association for Accessible Medicines (AAM) lays out a stark warning: the very medicines that keep the US healthcare system affordable and functioning are at risk. Generics and biosimilars fill nine out of ten prescriptions yet account for a tiny slice of spending, and new AAM–IQVIA data shows…
Latest Report
